The Value of Online CME in the Multidisciplinary Care of Patients with NTRK Fusion-Positive Thyroid Cancer

被引：0
|
作者：
Worst, M. A. [1 ]
Carothers, A. [1 ]
Surducan, M. [1 ]
Sipos, J. [2 ]
Wirth, L. [3 ]
机构：
[1] Medscape LLC, New York, NY USA
[2] Arthur G James Comprehens Canc Ctr, Columbus, OH USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 112卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
187
引用
收藏
页码：E50 / E51
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
    Waguespack, Steven G.
    Drilon, Alexander
    Lin, Jessica J.
    Brose, Marcia S.
    McDermott, Ray
    Almubarak, Mohammed
    Bauman, Jessica
    Casanova, Michela
    Krishnamurthy, Anuradha
    Kummar, Shivaani
    Leyvraz, Serge
    Oh, Do-Youn
    Park, Keunchil
    Sohal, Davendra
    Sherman, Eric
    Norenberg, Ricarda
    Silvertown, Josh D.
    Brega, Nicoletta
    Hong, David S.
    Cabanillas, Maria E.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2022, 186 (06) : 631 - 643
  • [32] Management of Patients with NTRK Fusion- Positive Lung Cancer
    Drilon, Alexander
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (06)
  • [33] Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer
    Cho, Byoung Chul
    Chiu, Chao-Hua
    Massarelli, Erminia
    Buchschacher, Gary L.
    Goto, Koichi
    Overbeck, Tobias R.
    Loong, Herbert H. F.
    Chee, Cheng E.
    Garrido, Pilar
    Dong, Xiaorong
    Fan, Yun
    Lu, Shun
    Schwemmers, Sven
    Bordogna, Walter
    Zeuner, Harald
    Osborne, Stuart
    John, Thomas
    LUNG CANCER, 2024, 188
  • [34] THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB VS. LENVATINIB OR SORAFENIB FOR TREATMENT OF NTRK FUSION-POSITIVE METASTATIC THYROID CANCER
    Carlson, J.
    Suh, K.
    Xia, F.
    Williamson, T.
    Sullivan, S.
    VALUE IN HEALTH, 2021, 24 : S20 - S20
  • [35] Off-target resistance to larotrectinib in two patients with NTRK fusion-positive pediatric solid tumors
    Lu, S.
    Xie, W.
    Zhang, Y.
    Sun, F.
    Huang, J.
    Wang, J.
    Zhu, J.
    Zhen, Z.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2023, 34 (11) : 1065 - 1067
  • [36] Uterin spindle cell mesenchymal neoplazm, NTRK fusion-positive uterine sarcoma
    Konuk, B.
    Topal, C. S.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S264 - S264
  • [37] NTRK Fusion-Positive Congenital Spinal Glioblastoma treated with Carboplatin, Etoposide, and Larotrectinib
    Vallis, Graham
    PEDIATRICS, 2021, 147 (03)
  • [38] Canadian consensus on TRK-inhibitor therapy for NTRK fusion-positive sarcoma
    Simmons, Christine
    Deyell, Rebecca J.
    MacNeill, Andrea J.
    Vera-Badillo, Francisco E.
    Smrke, Alannah
    Abdul Razak, Albiruni R.
    Banerji, Shantanu
    McLeod, Deanna
    Noujaim, Jonathan
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (09) : 1691 - 1704
  • [39] Clinical and analytic validation of FoundationOne CDx™ for NTRK fusion-positive solid tumors in patients treated with entrectinib
    Fabrizio, David
    Milbury, Coren
    Yip, Wai-Ki
    Yilmazel, Bahar
    Bai, Xiaobo
    Liao, Juan
    Smith, David
    Burns, Christine
    Vietz, Christine
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [40] Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline
    Dziadziuszko, R.
    Siena, S.
    Tan, D. S. W.
    Cho, B. C.
    Ahn, M-J.
    Goto, K.
    Garrido-Lopez, P.
    Farago, A. F.
    Loong, H. H. F.
    Tosi, D.
    John, T.
    Wolf, J.
    Chiu, C-H.
    Liu, S. V.
    Patel, M. R.
    Drilon, A.
    Pitcher, B.
    Simmons, B.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2020, 31 : S833 - S834
12345